Pablo
Aguiar Fernández
University of Padua
Padua, ItaliaPublicacións en colaboración con investigadores/as de University of Padua (2)
2023
-
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
European Journal of Nuclear Medicine and Molecular Imaging
2005
-
Management of acute coronary syndromes [1] (multiple letters)
New England Journal of Medicine